Inhibikase Therapeutics (IKT) Return on Equity (2020 - 2024)
Historic Return on Equity for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to 0.17%.
- Inhibikase Therapeutics' Return on Equity rose 86200.0% to 0.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17%, marking a year-over-year increase of 86200.0%. This contributed to the annual value of 0.54% for FY2024, which is 7100.0% up from last year.
- Latest data reveals that Inhibikase Therapeutics reported Return on Equity of 0.17% as of Q3 2025, which was up 86200.0% from 0.23% recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Return on Equity ranged from a high of 0.17% in Q3 2025 and a low of 8.79% during Q3 2024
- Over the past 5 years, Inhibikase Therapeutics' median Return on Equity value was 0.61% (recorded in 2024), while the average stood at 1.26%.
- Its Return on Equity has fluctuated over the past 5 years, first tumbled by -76300bps in 2024, then surged by 86200bps in 2025.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Return on Equity stood at 0.36% in 2021, then tumbled by -116bps to 0.78% in 2022, then crashed by -97bps to 1.55% in 2023, then skyrocketed by 61bps to 0.61% in 2024, then soared by 72bps to 0.17% in 2025.
- Its Return on Equity stands at 0.17% for Q3 2025, versus 0.23% for Q2 2025 and 0.26% for Q1 2025.